Andrew Harnik via Getty Images Long-time Tesla bull Dan Ives, an analyst at Wedbush Securities, says Elon Musk is the only one who can turn the EV maker's reputation around and the billionaire ...

Wedbush analysts called Palantir one of their "top names" to own in 2025 despite recent losses. Shares of Palantir have lost one-third of their value in the wake of a report last month that the ...

Long-time Tesla bull Dan Ives, an analyst at Wedbush Securities, says Elon Musk is the only one who can turn the EV maker's reputation around and the billionaire needs to show he is balancing his ...

As previously reported, Wedbush upgraded National CineMedia (NCMI) to Outperform from Neutral with a $7.50 price target The firm believes the company stands to gain from a strong box office ...

Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.51) per share for the quarter, up from their prior estimate of ($0.72). Wedbush has a “Outperform ...

Wedbush maintained its Outperform rating on Apple (NASDAQ:AAPL) noting that the company's next stage of product and AI driven services growth is still ahead. The firm has a $325 price target on ...

View Our Latest Analysis on NHI National Health Investors Stock Down 0.6 % NHI stock opened at $75.58 on Tuesday. National Health Investors has a 12 month low of $57.80 and a 12 month high of $86. ...

In a report released on March 14, David Nierengarten from Wedbush maintained a Buy rating on Generation Bio (GBIO – Research Report), with a price target of $5.00. The company’s shares closed ...

Delays in AI improvements and the next-generation Siriwhich are currently anticipated with iPhone 17have put pressure on Apple shares, claims Wedbush analyst Daniel Ives. A sluggish tech ...

Salesforce CEO Marc Benioff has berated Big Tech peers for their spending on AI and data centers, questioning whether companies like Microsoft are seeing real returns on their massive investments.

Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an Outperform recommendation, citing its lead asset obexelimab’s safety ...

Frank founder Charlie Javice kicked off her defense case with some firepower at her JPMorgan Chase fraud trial Thursday — calling private equity billionaire Marc Rowan to the witness stand.